Use of Ulipristal Acetate in Induction of Second Trimester Missed Abortion
Use of Ulipristal Acetate in Induction of Second Trimester Missed Abortion in Women With Previous Caesarian Section: A Randomized Controlled Trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Abbaseya
-
Cairo, Abbaseya, Egypt
- Ain Shams Maternity Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: • Women with 2nd trimester missed abortions
- Gestational age 13-26 weeks.
- Women with a previous caesarian section scar,(para 1cs till para 4 cs).
- Women counseled and chose medication abortion rather than surgical evacuation
Exclusion Criteria:
- Women with an accompanying medical disorder such as: Preeclampsia, Diabetes Mellitus or Heart disease.
- Primigravida women or non scarred uterus.
- Women with previous myomectomy or hysterotomy scar or upper segment caesarean section scar.
- Induction of abortion in women with congenital fetal malformations or positive fetal pulsations due to medical disorder.
- Women with placenta previa .
- Allergy or contraindications to either Ulipristal acetate or Misoprostol.
- Women with inevitable abortion in the form of vaginal bleeding or uterine contractions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ulipristal group
received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal according to FIGO guidelines 2017,Then women had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes.
If failed, patient proceeded to hysterotomy
|
Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal.
Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes.
If failed, patient proceeded to hysterotomy.
If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity.
Patient with remnants of conception proceeded suction evacuation.
Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal.Group B: received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal.
Then women in both groups had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes.
If failed, patient proceeded to hysterotomy.
If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity.
Patient with remnants of conception proceeded suction evacuation.
|
|
Placebo Comparator: placebo
received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal according to FIGO guidelines 2017.
Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes.
If failed, patient proceeded to hysterotomy
|
Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal.Group B: received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal.
Then women in both groups had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes.
If failed, patient proceeded to hysterotomy.
If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity.
Patient with remnants of conception proceeded suction evacuation.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Induction-to-abortion interval time.
Time Frame: 2 weeks
|
calculate the time needed from start of intervention till abortion occured
|
2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
complete evacuation between both groups
Time Frame: 2 weeks
|
number of patients experienced complete abortion between both groups
|
2 weeks
|
|
need for hysterotomy
Time Frame: 2 weeks
|
number of patients underwent hysterotomy
|
2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pregnancy Complications
- Abortion, Spontaneous
- Abortion, Missed
- Physiological Effects of Drugs
- Gastrointestinal Agents
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Anti-Ulcer Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Oxytocics
- Misoprostol
- Ulipristal acetate
Other Study ID Numbers
Other Study ID Numbers
- 5181
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.